Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax plus low-dose cytarabine for relapsed acute myeloid leukemia
ACTRN12619000746134Phase 2Recruiting
- Sponsor
- The Alfred Hospital
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax and cytarabine in acute myeloid leukemia (AML), sponsored by The Alfred Hospital. Primary endpoint: Remission or minimal residual disease response rate. Started Dec 2019; status: recruiting.
02
Drugs
venetoclaxcytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ACTRN12619000746134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000746134.